Rockefeller Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Rockefeller Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$190K	Sell	5,071 -391	-7%	-$14.5K	﹤0.01%	2629
2026 Q1	$198K	Buy	5,462 +783	+17%	+$35K	﹤0.01%	2500
2025 Q4	$218K	Buy	4,679 +521	+13%	+$23.2K	﹤0.01%	2323
2025 Q3	$173K	Buy	+4,158	New	+$133K	﹤0.01%	2302
2023 Q1	–	Sell	-1,000	Closed	-$18K	–	2363
2022 Q4	$18K	Hold	1,000	–	–	﹤0.01%	2841
2022 Q3	$19K	Buy	+1,000	New	+$20.4K	﹤0.01%	2790
2020 Q1	–	Sell	-7,066	Closed	-$177K	–	2371
2019 Q4	$177K	Buy	7,066 +4,053	+135%	+$77.2K	﹤0.01%	802
2019 Q3	$45K	Sell	3,013 -148	-5%	-$2.88K	﹤0.01%	994
2019 Q2	$79K	Hold	3,161	–	–	﹤0.01%	737
2019 Q1	$72K	Hold	3,161	–	–	﹤0.01%	834
2018 Q4	$95K	Hold	3,161	–	–	﹤0.01%	461
2018 Q3	$91K	Buy	+3,161	New	+$93.9K	﹤0.01%	398

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's CRNX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 7.2% in Q2 2026, selling an estimated $14.5K and leaving 5,071 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #2629.

Rockefeller Capital Management first reported a position in CRNX in Q3 2018 and has held it in 12 quarters since. The position peaked at $218K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Rockefeller Capital Management held 5,071 shares of Crinetics Pharmaceuticals worth $190K as of Q2 2026.
Rockefeller Capital Management sold 391 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $14.5K.
Crinetics Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2629 holding.
Rockefeller Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
Rockefeller Capital Management's Crinetics Pharmaceuticals position peaked at $218K in Q4 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.